Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools for $350 million in cash plus contingent payments, expanding Illumina’s footprint in proteomics and multiomics. The deal adds SomaLogic’s SomaScan aptamer platform and a CLIA/CAP-certified lab in Boulder, Colorado, and aligns with Illumina’s Protein Prep sequencing-based readout. Illumina said it will leverage its NGS ecosystem and DRAGEN software to integrate protein-level assays with genomic workflows, positioning the company to push multiomics at scale for discovery and translational customers.